Pipeline
KBP-5074 for CV disease/Hypertension in CKD patients – Finish Phase 2a / Ready for global Phase 2b
KBP-7072 for multiple drug resistant infections– Finish Phase 1 / Ready for global Phase 2
KBP-7026 novel CRTH2 receptor antagonist targeting asthma/COPD -- Ready for Phase 1
MANAGEMENT TEAM
• Zhenhua Huang, PhD/MBA, Founder/Chairman
• Fred Yang, PhD,CDO
• Robert Segal, MD,Deputy CMO
• Vince Benn, PhD/MBA,VP
• Pual Chow, PhD,VP
ADVISORY BOARD
• Bertram Pitt, MD (US)
• George Bakris, MD (US)
• John McMurray, MD (UK)
• Faiez Zannad, MD (FR)
• Ricard Wunderink, MD (US)
Positive FDA Type B Meeting on KBP-5074
KBP-7072 obtained QIDP and Fast Track Designations
Presenting the annual meeting of the American Society of Nephrology (ASN)
Presenting the 2016 China BioMed Innovation and Investment Conference
Fred Yang, Ph.D, Chief Development Officer fred.yang@kbpbiosciences.com
116 Village Blvd., Suite 210 Princeton, NJ 08540 Phone: (609) 531-0889(Office) / (267)980-9451(Cell)
